These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19526195)

  • 1. Multifocal myoclonus induced by haloperidol.
    Domínguez C; Benito-León J; Bermejo-Pareja F
    Neurol Sci; 2009 Oct; 30(5):385-6. PubMed ID: 19526195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease.
    Auchus AP; Bissey-Black C
    J Neuropsychiatry Clin Neurosci; 1997; 9(4):591-3. PubMed ID: 9447502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Alzheimer's disease.
    De Deyn PP
    N Engl J Med; 2000 Mar; 342(11):821; author reply 821-2. PubMed ID: 10722341
    [No Abstract]   [Full Text] [Related]  

  • 4. Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial.
    Verhey FR; Verkaaik M; Lousberg R;
    Dement Geriatr Cogn Disord; 2006; 21(1):1-8. PubMed ID: 16244481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease.
    Tune LE; Steele C; Cooper T
    Psychiatr Clin North Am; 1991 Jun; 14(2):353-73. PubMed ID: 1676507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine-induced myoclonic status.
    Camacho A; García-Navarro M; Martínez B; Villarejo A; Pomares E
    Clin Neuropharmacol; 2005; 28(3):145-7. PubMed ID: 15965316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone and dementia-related aggression: new indication. A last resort, no better than haloperidol.
    Prescrire Int; 2009 Dec; 18(104):248. PubMed ID: 20025088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances.
    Suh GH; Son HG; Ju YS; Jcho KH; Yeon BK; Shin YM; Kee BS; Choi SK
    Am J Geriatr Psychiatry; 2004; 12(5):509-16. PubMed ID: 15353389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine-associated myoclonus.
    Rosen JB; Milstein MJ; Haut SR
    Epilepsy Res; 2012 Feb; 98(2-3):247-50. PubMed ID: 22196307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haloperidol-induced myoclonus in a patient with delirium.
    Hayase T; Saiga H; Yamaguchi T
    Geriatr Gerontol Int; 2023 Mar; 23(3):243-244. PubMed ID: 36709514
    [No Abstract]   [Full Text] [Related]  

  • 11. Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects.
    Lane HY; Chang YC; Su MH; Chiu CC; Huang MC; Chang WH
    J Clin Psychopharmacol; 2002 Feb; 22(1):4-10. PubMed ID: 11799336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone.
    Meibach RC
    Neurology; 2000 Oct; 55(7):1069. PubMed ID: 11061283
    [No Abstract]   [Full Text] [Related]  

  • 13. Tardive Myoclonus Responsive to Clozapine Misdiagnosed as Restless Leg Syndrome: A Case Report.
    Selçuk M
    J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):692-694. PubMed ID: 34459435
    [No Abstract]   [Full Text] [Related]  

  • 14. Possible toxic encephalopathy following high-dose intravenous haloperidol.
    Maxa JL; Taleghani AM; Ogu CC; Tanzi M
    Ann Pharmacother; 1997 Jun; 31(6):736-7. PubMed ID: 9184715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol.
    McSwain ML; Forman LM
    J Clin Psychopharmacol; 1995 Aug; 15(4):284. PubMed ID: 7593712
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroleptic malignant syndrome and cardiac surgery. A case report.
    Sirois F
    J Cardiovasc Surg (Torino); 2008 Oct; 49(5):695-6. PubMed ID: 18670390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of haloperidol in the agitated, critically ill pediatric patient with burns.
    Brown RL; Henke A; Greenhalgh DG; Warden GD
    J Burn Care Rehabil; 1996; 17(1):34-8. PubMed ID: 8808357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?
    Sultzer DL; Gray KF; Gunay I; Wheatley MV; Mahler ME
    J Am Geriatr Soc; 2001 Oct; 49(10):1294-300. PubMed ID: 11890487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient.
    D'Souza DC; Bennett A; Abi-Dargham A; Krystal JH
    J Clin Psychopharmacol; 1994 Oct; 14(5):361-3. PubMed ID: 7806697
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversible anorexia and rapid weight loss associated with neuroleptic administration in Alzheimer's disease.
    Rohrbaugh RM; Siegal AP
    J Geriatr Psychiatry Neurol; 1989; 2(1):45-7. PubMed ID: 2568117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.